Patents by Inventor Matthias Wiesner
Matthias Wiesner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8410143Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: June 19, 2009Date of Patent: April 2, 2013Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Patent number: 7915228Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.Type: GrantFiled: June 2, 2008Date of Patent: March 29, 2011Assignee: Tioga Pharmaceuticals, Inc.Inventors: Matthias Wiesner, Christoph Seyfried
-
Patent number: 7691870Abstract: The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients.Type: GrantFiled: June 11, 2004Date of Patent: April 6, 2010Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg
-
Patent number: 7691886Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.Type: GrantFiled: June 15, 2004Date of Patent: April 6, 2010Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Dirk Finsinger, Matthias Wiesner, Lars Thore Burgdorf, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Patent number: 7648959Abstract: Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors ?v ?3 and/or ?v ?5. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.Type: GrantFiled: June 7, 2006Date of Patent: January 19, 2010Assignee: Merck Patent GmbHInventors: Hans-Markus Bender, Jutta Haunschild, Matthias Wiesner, Ulrich Lang, Martin Friedlander
-
Patent number: 7645736Abstract: Methods for the treatment of a disease of the eye of a patient comprising injecting into the vitreous body of the eye a composition comprising a therapeutically effective amount of an ?v?3 and/or ?v?5 inhibitor sufficient to inhibit angiogenesis and inhibit neovascularization in the treated eye. The ?v?3 and/or ?v?5 inhibitor being a compound of formula II: as defined herein or a physiologically acceptable salt thereof.Type: GrantFiled: August 28, 2006Date of Patent: January 12, 2010Assignee: Merck Patent GmbHInventors: Hans-Markus Bender, Jutta Haunschild, Ulrich Lang, Matthias Wiesner, Martin Friedlander
-
Publication number: 20090298885Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: June 19, 2009Publication date: December 3, 2009Applicant: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Publication number: 20090253688Abstract: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: February 14, 2005Publication date: October 8, 2009Applicant: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Dirk Finsinger, Frank Stieber, Matthias Wiesner, Christiane Amendt, Christian Sirrenberg, Frank Zenke, Matthias Grell
-
Patent number: 7598274Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumoursType: GrantFiled: October 26, 2004Date of Patent: October 6, 2009Assignee: Merck Patent GmbHInventors: Dirk Finsinger, Hans-Peter Buchstaller, Lars Burgdorf, Matthias Wiesner, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Patent number: 7589112Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: October 8, 2003Date of Patent: September 15, 2009Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Publication number: 20090163556Abstract: The present invention relates to glycinamide derivatives of formula I, A-D-B??(I), wherein A, D, and B are as herein defined, as well as the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition, and a method of treatment comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: November 18, 2008Publication date: June 25, 2009Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
-
Patent number: 7476683Abstract: The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: July 31, 2003Date of Patent: January 13, 2009Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
-
Publication number: 20080234209Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.Type: ApplicationFiled: June 2, 2008Publication date: September 25, 2008Inventors: Matthias WIESNER, Christoph SEYFRIED
-
Patent number: 7385065Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.Type: GrantFiled: November 25, 2003Date of Patent: June 10, 2008Assignee: Tioga Pharmaceuticals, Inc.Inventors: Matthias Wiesner, Christoph Seyfried
-
Patent number: 7371854Abstract: Process for the preparation of integrin inhibitors of the formula (I), in which R1, R2, R3, R4, R5 and X have the meanings indicated in Claim 1, and intermediate compoundsType: GrantFiled: January 14, 2004Date of Patent: May 13, 2008Assignee: Merck Patent GmbHInventors: Matthias Wiesner, Bernd Neff
-
Publication number: 20070213374Abstract: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.Type: ApplicationFiled: June 18, 2004Publication date: September 13, 2007Applicant: Merck Patent GmbHInventors: David Bruge, Hans-Peter Buchstaller, Matthias Wiesner, Dirk Finsinger, Manfred Baumgarth, Christian Sirrenberg, Frank Zenke, Christian Amendt, Matthias Grell
-
Publication number: 20070179098Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the said pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the said pharmaceutical composition.Type: ApplicationFiled: April 2, 2007Publication date: August 2, 2007Inventors: Matthias Wiesner, Christoph Seyfried
-
Publication number: 20070149594Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumoursType: ApplicationFiled: October 26, 2004Publication date: June 28, 2007Inventors: Dirk Finsinger, Hans-Peter Buchstaller, Lars Burgdorf, Matthias Wiesner, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Publication number: 20070117849Abstract: This invention relates to inhibition of ?v integrins, especially ?v?3 and ?v?6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells/myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis/cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.Type: ApplicationFiled: September 16, 2004Publication date: May 24, 2007Inventors: Simon Goodman, Detlef Schuppan, Eleonora Patsenker, Yury Popov, Michael Bauer, Matthias Wiesner, Alfred Jonczyk
-
Publication number: 20070093532Abstract: The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.Type: ApplicationFiled: June 11, 2004Publication date: April 26, 2007Applicant: MERCK PATENT GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg